The Uttar Pradesh Government signed Memorandums of Understanding (MoUs) worth an estimated 10,000 INR-Crore with pharmaceutical companies. These MoUs were signed at the UP Pharma Conclave in Lucknow on February 3. The agreements mark a significant step in positioning the state as a hub for pharma manufacturing and innovation.
Key Investments at the UP Pharma Conclave
- Arna Pharma – 1,250 INR-Crore
- Biogenta Life Science – 1,250 INR-Crore
- Shukra Pharmaceuticals – 737 INR-Crore
- Walter Bushnell Enterprise – 590 INR-Crore
- Jhanvika Labs – 553 INR-Crore
- Koro Health – 418 INR-Crore
- Mark Laboratories – 300 INR-Crore
- High Glance Laboratories – 120 INR-Crore
- Raspa Pharma – 107 INR-Crore
- Romsons Medworld – 100 INR-Crore
- Kotak Healthcare – 100 INR-Crore
Also Read: Union Budget 2026-27: Impact on India’s Construction Sector
The UP Pharma Conclave is part of the state’s plan to establish itself as a manufacturing and innovation hub in the pharma sector. The government is actively promoting AI, telemedicine, deep tech, med tech, health tech, and clinical research.
A major highlight is the upcoming ‘Bulk Drug Pharma Park’ in Lalitpur, designed on a hub-and-spoke model with advanced research and development facilities. New pharma parks will also be developed in Bareilly and other districts to expand the ecosystem.
Biltrax Construction Data is tracking 37,000+ projects on their technology platform for their clients.
Get exclusive access to upcoming projects in India with actionable insights. Furthermore, gain a competitive advantage for your products in the Indian Construction Market.
Visit www.biltrax.com or email us at contact@biltrax.com to become a subscriber and generate leads.
Disclaimer: The information herein is based upon information obtained in good faith from sources believed to be reliable. All such information and opinions can be subject to change. Furthermore, the image featured in this article is for representation purposes only. It does not in any way represent the project. If you wish to remove or edit the article, please email editor@biltrax.com.
0Discover more from Biltrax Media, A Biltrax Group venture
Subscribe to get the latest posts sent to your email.
